Narmafotinib is under clinical development by Amplia Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Narmafotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Narmafotinib overview
AMP-945 (CTX-0294945) is under development for the treatment of chemotherapy-resistant high-grade serous ovarian cancer, idiopathic pulmonary fibrosis, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, scar reduction, wounds, burns, non-alcoholic steatohepatitis (NASH), other solid tumors and other fibrotic diseases. It is a small molecule administered through oral route. It acts by targeting focal adhesion kinase (FAK).
The drug candidate was also under development for the treatment of triple negative breast cancer, squamous cell carcinoma, fibrotic interstitial lung diseases and solid tumor.
Amplia Therapeutics overview
Amplia Therapeutics is a clinical-stage, drug development company. It develops orally available inhibitors of focal adhesion kinase (FAK) for the treatment of cancer and fibrotic diseases. The company’s pipeline products include AMP945; is a small molecule targeting focal adhesion kinase (FAK) in fibrotic tumors such as pancreatic and other drug candidates and AMP886; is a multi-action molecule targeting VEGFR3 and FLT3 cancer pathways in solid and hematological cancers. Amplia Therapeutics is headquartered in North Melbourne, Victoria, Australia.
For a complete picture of Narmafotinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
